• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对阻塞性肺病患者的药物使用回顾性研究。药物治疗质量评估。

A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.

作者信息

Van den Brink G, Bollen C W, Van de Wall O E, Hoeve L J, Porsius A J

机构信息

Department of Pharmacotherapy, University of Utrecht, The Netherlands.

出版信息

Pharm Weekbl Sci. 1992 Oct 16;14(5):311-5. doi: 10.1007/BF01977619.

DOI:10.1007/BF01977619
PMID:1359504
Abstract

This study presents the results of an analysis of the pharmacy records of 778 patients with asthma or chronic obstructive lung diseases. The high percentage of patients taking oral corticosteroids was striking. Inhaled beta-agonists for use as needed have been prescribed to only a minority of patients using these agents. Only half of the patients on beta-agonists used inhaled corticosteroids prophylactically. Drug interactions capable of causing changes in plasma theophylline concentrations appeared in only a small number of patients. The results from studies like the one presented here can provide valuable data to be used for further discussion between physicians and pharmacists about rational drug therapy.

摘要

本研究展示了对778例哮喘或慢性阻塞性肺疾病患者的药房记录分析结果。服用口服皮质类固醇的患者比例之高令人瞩目。按需使用的吸入型β受体激动剂仅被开给了少数使用这些药物的患者。使用β受体激动剂的患者中只有一半预防性使用吸入型皮质类固醇。仅少数患者出现了能够引起血浆茶碱浓度变化的药物相互作用。像这里展示的这类研究结果可为医生和药剂师之间关于合理药物治疗的进一步讨论提供有价值的数据。

相似文献

1
A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.一项针对阻塞性肺病患者的药物使用回顾性研究。药物治疗质量评估。
Pharm Weekbl Sci. 1992 Oct 16;14(5):311-5. doi: 10.1007/BF01977619.
2
Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids.长效β受体激动剂对已接受吸入性糖皮质激素治疗的持续性哮喘患者的治疗作用
BioDrugs. 2001;15(1):11-24. doi: 10.2165/00063030-200115010-00002.
3
A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.吸入长效β2受体激动剂治疗阻塞性肺疾病的获益-风险评估
Drug Saf. 2004;27(10):689-715. doi: 10.2165/00002018-200427100-00001.
4
Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.哮喘药物及其在老年人中的潜在不良反应:处方建议
Drug Saf. 2001;24(14):1065-80. doi: 10.2165/00002018-200124140-00005.
5
[The place of long-acting beta 2 adrenergic agonists in the treatment of asthma and chronic obstructive lung disease (COPD)].长效β2肾上腺素能激动剂在哮喘和慢性阻塞性肺疾病(COPD)治疗中的地位
Ned Tijdschr Geneeskd. 1999 Jan 16;143(3):137-40.
6
Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Current thinking, practices, and controversies.
Arch Intern Med. 1993 Apr 12;153(7):814-28.
7
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2006 Oct 18(4):CD003137. doi: 10.1002/14651858.CD003137.pub3.
8
[Use of drugs for CNSLD (asthma and COPD) in Dutch residential homes and nursing homes].[荷兰养老院和疗养院中用于慢性非特异性肺部疾病(哮喘和慢性阻塞性肺疾病)的药物使用情况]
Tijdschr Gerontol Geriatr. 1997 Jun;28(3):101-5.
9
Maintenance drug therapy of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的维持药物治疗
Am J Manag Care. 1999 Jan;5(1):91-7; quiz 98-9.
10
Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.白三烯受体拮抗剂和长效β2肾上腺素受体激动剂与吸入性糖皮质激素联合治疗哮喘的耐受性概况:一项综述
J Asthma. 2007 Jul-Aug;44(6):411-22. doi: 10.1080/02770900701247178.

引用本文的文献

1
Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.布地奈德:对其在哮喘治疗中药物经济学及生活质量效益依据的评估
Pharmacoeconomics. 1995 May;7(5):457-70. doi: 10.2165/00019053-199507050-00009.
2
Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England.制定基层医疗处方行为标准:利用全科医生共识小组并将标准应用于英格兰北部的医疗机构
Br J Gen Pract. 1996 Jan;46(402):20-5.
3
The use of hypoglycaemic and cardiovascular drugs in 582 patients with diabetes mellitus. Description and quality assessment.

本文引用的文献

1
Improving the care of asthmatic patients in general practice.改善基层医疗中哮喘患者的护理。
Br Med J (Clin Res Ed). 1983 Jun 25;286(6383):2027-30. doi: 10.1136/bmj.286.6383.2027.
2
Steroids and "steroid-sparing" agents in asthma.哮喘治疗中的类固醇及“类固醇节省剂”
N Engl J Med. 1988 Mar 10;318(10):634-6. doi: 10.1056/NEJM198803103181010.
3
Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD. Comparison with cimetidine and placebo.
Chest. 1988 Oct;94(4):807-10. doi: 10.1378/chest.94.4.807.
582例糖尿病患者使用降糖药和心血管药物的情况。描述与质量评估。
Pharm World Sci. 1993 Jun 18;15(3):128-31. doi: 10.1007/BF02113941.
4
Impact of beta 1 selectivity and intrinsic sympathomimetic activity on potential unwanted noncardiovascular effects of beta blockers.β1选择性和内在拟交感活性对β受体阻滞剂潜在不良非心血管效应的影响。
Am J Cardiol. 1987 May 15;59(13):44F-47F. doi: 10.1016/0002-9149(87)90041-5.
5
Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug.β-肾上腺素能阻滞剂中β1选择性和内在拟交感活性的临床意义。
Am J Cardiol. 1987 May 15;59(13):33F-37F. doi: 10.1016/0002-9149(87)90039-7.
6
Perspective on asthma mortality--1989.1989年哮喘死亡率透视
Ann Allergy. 1989 Dec;63(6 Pt 2):578-84.
7
Management of asthma in general practice.全科医疗中哮喘的管理
Respir Med. 1989 Jan;83(1):67-70. doi: 10.1016/s0954-6111(89)80062-9.
8
A new approach to the treatment of asthma.一种治疗哮喘的新方法。
N Engl J Med. 1989 Nov 30;321(22):1517-27. doi: 10.1056/NEJM198911303212206.
9
Difficult asthma.难治性哮喘
BMJ. 1989 Sep 16;299(6701):695-8. doi: 10.1136/bmj.299.6701.695.
10
Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.
Eur J Clin Pharmacol. 1990;38(1):43-5. doi: 10.1007/BF00314801.